Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BEBT-260 by Guangzhou BeBetter Medicine Technology for Non-Small Cell Lung Cancer: Likelihood of Approval
BEBT-260 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Non-Small Cell Lung Cancer....
BEBT-260 by Guangzhou BeBetter Medicine Technology for Ovarian Cancer: Likelihood of Approval
BEBT-260 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Ovarian Cancer. According to...
BEBT-260 by Guangzhou BeBetter Medicine Technology for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
BEBT-260 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Kidney Cancer (Renal Cell...
BEBT-260 by Guangzhou BeBetter Medicine Technology for Colon Cancer: Likelihood of Approval
BEBT-260 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Colon Cancer. According to...
BEBT-260 by Guangzhou BeBetter Medicine Technology for Vulvar Cancer: Likelihood of Approval
BEBT-260 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Vulvar Cancer. According to...
BEBT-260 by Guangzhou BeBetter Medicine Technology for Anal Cancer: Likelihood of Approval
BEBT-260 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Anal Cancer. According to...
BEBT-260 by Guangzhou BeBetter Medicine Technology for Solid Tumor: Likelihood of Approval
BEBT-260 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Solid Tumor. According to...
BEBT-260 by Guangzhou BeBetter Medicine Technology for Small-Cell Lung Cancer: Likelihood of Approval
BEBT-260 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Small-Cell Lung Cancer. According...
BEBT-260 by Guangzhou BeBetter Medicine Technology for Pancreatic Cancer: Likelihood of Approval
BEBT-260 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Pancreatic Cancer. According to...
BEBT-260 by Guangzhou BeBetter Medicine Technology for Breast Cancer: Likelihood of Approval
BEBT-260 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Breast Cancer. According to...
BEBT-260 by Guangzhou BeBetter Medicine Technology for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
BEBT-260 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Triple-Negative Breast Cancer (TNBC)....
BEBT-260 by Guangzhou BeBetter Medicine Technology for Gastric Cancer: Likelihood of Approval
BEBT-260 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Gastric Cancer. According to...
BEBT-260 by Guangzhou BeBetter Medicine Technology for Penile Cancer: Likelihood of Approval
BEBT-260 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Penile Cancer. According to...
ZXBT-1158 by Guangzhou BeBetter Medicine Technology for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
ZXBT-1158 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Diffuse Large B-Cell Lymphoma....
ZXBT-1158 by Guangzhou BeBetter Medicine Technology for Mantle Cell Lymphoma: Likelihood of Approval
ZXBT-1158 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Mantle Cell Lymphoma. According...
ZXBT-1158 by Guangzhou BeBetter Medicine Technology for Follicular Lymphoma: Likelihood of Approval
ZXBT-1158 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Follicular Lymphoma. According to...
ZXBT-1158 by Guangzhou BeBetter Medicine Technology for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
ZXBT-1158 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)....
ZXBT-1158 by Guangzhou BeBetter Medicine Technology for Marginal Zone B-cell Lymphoma: Likelihood of Approval
ZXBT-1158 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Marginal Zone B-cell Lymphoma....